Drug Trial Radar · NCT07150338
Outcome of Use of a Novel Modulator of Oxidative Phosphorylation on Kidney Function in Patients With Progressive Chronic Kidney Disease
Last checked: Nov 19, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
May 20, 2021
Primary completion
Apr 20, 2022
Study completion Nov 20, 2022
Sponsor
- Lead sponsor
- Neukidney Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 2, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Outcome of use of a novel Modulator of Oxidative Phosphorylation on kidney function in patients with Chronic Kidney Disease
Conditions
- Chronic Kidney Disease (Stage 3-4)
- Chronic Kidney Disease (Stages 4 and 5)
- Proteinuria
Interventions
QRX-3Drug
Compounded new drug regime
EseronateDrug
Neukidney innovative drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Decrease rate of GFR declineTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Premier Kidney clinic
Pasadena, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.